Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

A woman wearing a mask walks by Gilead Sciences headquarters sign in Foster City, California on April 30, 2020. (Photo: Josh Edelson/AFP via Getty Images)

'Absolute Robbery': Gilead Announces $3,120 Price Tag for Covid-19 Drug Developed With $70 Million in Taxpayer Support

"Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic. Beyond disgusting," said Sen. Bernie Sanders.

Jake Johnson

Consumer advocates reacted with disgust Monday to an announcement by Gilead Sciences that it will charge U.S. hospitals around $3,120 per privately insured patient for a treatment course of remdesivir, a drug which has proven modestly effective at speeding Covid-19 recovery times.

"Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration."
—Peter Maybarduk, Public Citizen

Peter Maybarduk, director of Public Citizen's Access to Medicines Program, called Gilead's pricing—which works out to around $520 per dose for non-government buyers like hospitals—"an offensive display of hubris and disregard for the public" and slammed the Trump administration for failing to ensure that the price of a drug developed with substantial taxpayer support is affordable for all.

Maybarduk pointed to Institute for Clinical and Economic Review research showing Gilead could still make a profit by pricing remdesivir at $310 per course.

"Gilead has priced at several thousand dollars a drug that should be in the public domain. For $1 per day, remdesivir can be manufactured at scale with a reasonable profit," Maybarduk said in a statement. "Gilead did not make remdesivir alone. Public funding was indispensable at each stage, and government scientists led the early drug discovery team. Allowing Gilead to set the terms during a pandemic represents a colossal failure of leadership by the Trump administration."

Public Citizen estimated in a May report that U.S. taxpayers contributed at least $70.5 million to the development of remdesivir.

Shortly after Gilead's announcement, the U.S. Health and Human Services Department said it reached an agreement with the pharmaceutical giant to purchase more than 500,000 treatment courses of remdesivir for American hospitals.

The Wall Street Journal reported that the United States is "the only developed country where Gilead will charge two prices"—one for government buyers ($390 per dose) and one for non-government buyers like hospitals ($520 per dose). The typical remdesivir treatment course consists of around six doses.

"Trump's refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy."
—Rep. Lloyd Doggett

Unlike the U.S., the Journal notes, the governments of other advanced nations "negotiate drug prices directly with drugmakers."

Rep. Lloyd Doggett (D-Texas), chair of the House Ways and Means Health Subcommittee, said in a statement that "Trump's refusal to stop pandemic profiteering with a stroke of a pen is a green light to other manufacturers to exploit this tragedy."

Doggett said he is pressuring the Trump administration and Gilead to disclose the details of their agreement, including the sum the government paid for the 500,000 treatment courses of remdesivir.

On Twitter, Sen. Bernie Sanders (I-Vt.) condemned Gilead's price-tag as "beyond disgusting."

"Taxpayers provided funding for the development of this drug. Now Gilead is price-gouging off it during a pandemic," said Sanders. "Coronavirus treatment must be free to all."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

This is the world we live in. This is the world we cover.

Because of people like you, another world is possible. There are many battles to be won, but we will battle them together—all of us. Common Dreams is not your normal news site. We don't survive on clicks. We don't want advertising dollars. We want the world to be a better place. But we can't do it alone. It doesn't work that way. We need you. If you can help today—because every gift of every size matters—please do. Without Your Support We Simply Don't Exist.

As Other States Try to Copy Texas, SCOTUS Asked to Find Abortion Ban Unconstitutional

The request from healthcare providers comes after a Florida Republican filed a copycat bill and advocacy groups called on Congress to affirm the right to abortion nationwide.

Jessica Corbett ·


As Bids to Slash Pentagon Budget Fail, US Military Spending Slammed as 'Height of Absurdity'

"Spending $780 billion on weapons and war while our communities starve, while the climate crisis worsens, while a pandemic that has killed millions and affected countless more rages on, is a national shame."

Brett Wilkins ·


'This Is Big': House Passes Amendment to Cut US Complicity in Saudi Bombing of Yemen

The vote, said Rep. Ro Khanna, "sent a clear message to the Saudis: end the bombing in Yemen and lift the blockade."

Andrea Germanos ·


Praised for 'Braving the Smears,' Tlaib Votes Against $1 Billion in Military Aid to Israel

One rights group thanked Tlaib "for speaking truth to power" while being attacked "for simply insisting that Palestinians are human beings who deserve safety, security, and freedom from Israeli apartheid."

Brett Wilkins ·


'A Choice Point for Humanity': Women Demand Visionary Shift at UN Climate Talks

"This is the time to unite together to build the healthy and just future we know is possible for each other and the Earth."

Julia Conley ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo